Patients Eagerly Awaited a Generic Drug. Then They Saw the Price. - The New York Times
Teva Pharmaceuticals Moving U.S. Headquarters To New Jersey
Teva Pharmaceuticals - Wikipedia
Teva reports massive $11.6 billion loss, predicts weak 2018 - Business - Haaretz.com
Teva Pharmaceutical | P3 Properties | NJ Office Market
US Congress grills Teva CEO on Copaxone price hikes - Globes
Teva Pharmaceutical Industries and opioid settlement: What to know
Jury holds drugmaker Teva liable in opioid crisis | KGAN
Global Fluconazole Market 2018 - Pfizer, Bayer, Teva
Feds accuse Teva of $300M in kickbacks for MS drug - Drug Discovery and Development
Teva Becomes First Pharmaceutical Company to Execute Sustainability-Linked Bond Tied to Both Climate and Access to Medicine Targets | News Direct
/cloudfront-us-east-2.images.arcpublishing.com/reuters/ANJL4AXVTBOMDKS2X4DIJZXZAY.jpg "Teva loses bid to cancel Corcept drug patent at Federal Circuit | Reuters")
Teva loses bid to cancel Corcept drug patent at Federal Circuit | Reuters
Pharma giant Teva promises to create over 800 jobs in N.J. Are they worth $40M? - nj.com
Israel's Teva to move US HQ from Pennsylvania to New Jersey | The Times of Israel
18. Teva Pharmaceutical Industries | FiercePharma
FDA approves a generic version of Teva Pharmaceutical's best-selling drug; company shares tumble
15. Teva Pharmaceutical Industries | FiercePharma
Teva chief reports 'strong progress' in restructuring plan | The Times of Israel
Teva Pharmaceuticals: Israeli drugmaker to cut 14,000 jobs - BBC News
Teva Stock Dives As The Sales Downfall Continues For Its Biggest Product | Investor's Business Daily
Teva down as it reports lower sales and profit for 2018
Teva Selling $3.5 Billion of Junk Bonds to Refinance Debt - Bloomberg
Teva Pharm to lay off a quarter of workforce, suspends dividend | Reuters
Teva Reports Fourth Quarter and Full Year 2019 Financial Results | Business Wire
Teva Pharmaceutical falls 6% on eve of Q3 earnings show | Seeking Alpha
2017 closes with record approvals of generics, novel drugs; 2018 begins with reprieves for Teva | Radio Compass Blog
